Physician profile
Tara Starr
NPI 1124150065
$4,504.34
in general payments reported to CMS, 2019-2025
25 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,884 · 2020: $285 · 2021: $396 · 2022: $384 · 2023: $432 · 2024: $738 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,402.99 | 2019-2023 | |
| Alcon Vision LLC | $397.69 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Amgen INC. | $295.98 | 2019-2024 | Tepezza |
| Abbvie INC. | $258.51 | 2023-2025 | Vuity |
| Novo Nordisk INC | $241.56 | 2022 | |
| Glaukos Corporation | $202.16 | 2024 | |
| Amarin Pharma, INC. | $136.60 | 2019 | |
| Sight Sciences, INC. | $133.88 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $133.11 | 2022-2024 | Tyrvaya |
| Silk Road Medical, INC. | $129.13 | 2021 | |
| Ibsa Pharma INC. | $125.00 | 2021 | |
| Glaxosmithkline, LLC. | $121.83 | 2024 | Arexvy |
| Bausch & Lomb Americas INC. | $121.21 | 2023 | Miebo |
| Novartis Pharmaceuticals Corporation | $114.51 | 2020-2023 | |
| Intuitive Surgical, INC. | $100.64 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $100.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $78.92 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $70.25 | 2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.32 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $68.25 | 2024 | Xdemvy |
| Allergan, INC. | $67.50 | 2020-2021 | |
| Horizon Therapeutics Plc | $55.64 | 2021-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $45.80 | 2020-2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $15.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.